SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

VLR258

TCRT·Alaunos Therapeutics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Not stated
Time to market
Not stated
Why 2/10
No hard dated catalyst (PDUFA, pivotal readout, or regulatory decision) is scheduled for VLR258 in the next ~12 months; the drug is not mentioned in any public source from the Velaris acquisition announcement or subsequent filings, and appears to be a preclinical or very early-stage asset with no clinical trial record found.
Actionable Insight NEUTRAL

VLR258 is not referenced in any public disclosure from Alaunos Therapeutics or its Velaris acquisition. Investors should watch for the company to formally unveil its full pipeline post-merger; until then, VLR258 appears to be a preclinical or early discovery-stage program with no near-term catalyst.

Price Chart

Loading chart...

Executive Summary

VLR258 is a pipeline candidate acquired by Alaunos Therapeutics (NASDAQ: TCRT) through its October 2026 reverse merger with Velaris Therapeutics. The drug is not named in any public press release, SEC filing, or clinical trial registry found during research. The only named Velaris program is VLR199, an ActRIIA-Fc ligand trap for pulmonary arterial hypertension with proof-of-concept data expected in 2028. VLR258 appears to be a preclinical or early discovery-stage asset with no disclosed mechanism, trial data, or regulatory timeline, making it impossible to evaluate as an investment thesis driver.

How It Works

Unknown. Based on the Velaris pipeline description (ActRII-Fc portfolio for pulmonary arterial hypertension), VLR258 may be an activin-signaling inhibitor, but no specific mechanism has been disclosed.

Trial Status

No clinical trials or public development data were found for VLR258. The Velaris acquisition press release and the company's SEC filings mention only VLR199 as the lead ActRIIA-Fc program for PAH, with proof-of-concept data expected in 2028.

The Two-Sided Case

▲ Bull Case0
▼ Bear Case3
VLR258 is not mentioned in any public source, SEC filing, or press release from Alaunos Therapeutics or Velaris, suggesting it is either a very early preclinical program or a discontinued candidate.
The Velaris acquisition press releases and SEC filings highlight only VLR199 as the lead PAH program; VLR258's existence is unconfirmed in any official disclosure.
Alaunos Therapeutics has a history of Nasdaq compliance issues, dilutive financings, and a complete pipeline pivot from oncology to PAH via the Velaris reverse merger, creating significant execution risk for any unvalidated early-stage asset.

Upcoming Catalysts

  • Alaunos may release a combined pipeline update post-Velaris merger that could clarify VLR258's status and development stage.
  • VLR199 proof-of-concept data expected in 2028 is the nearest named pipeline catalyst for the combined company.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Alaunos Therapeutics, Inc. S-3 TCRT ·Originating report

Sources · 7

Hover a chip for the title
1 morningstar.com2 msn.com3 marketscreener.com4 marketwatch.com5 theglobeandmail.com6 msn.com7 sec.gov